March 25, 2016
(STAT News) – True to its widely vilified business model, the drug maker more than doubled the price of Seconal, a drug used for physician-assisted suicide, from $1,500 to $3,000, early last year. This occured a few months before California lawmakers proposed legalizing the practice (it was signed into law last October). The company was able to readily slap a higher price on the drug because there are no generics available, although a compound version can be obtained.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.